Impact of Age and Polytherapy on Fingolimod Induced Bradycardia: a Preclinical Study
- 1 February 2017
- journal article
- research article
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 12 (1) , 204-209
Abstract
Fingolimod is a an oral disease modifying drug for relapsing remitting multiple sclerosis (MS) preventing egress of B and T cells from lymph nodes. Relevant first dose adverse events include bradycardia and atrioventricular conduction slowing. Cardiac side effects of fingolimod and combinational pharmacotherapy including duloxetine and tolterodine were monitored in mice of different age using implantable ECG telemetric systems. Cardiac tissue was assessed for S1P-receptor subtype (1 and 3), and for GIRK1 expression. Fingolimod led to a significant heart rate reduction within 60 min, which returned to baseline values within 24 h. In older mice bradycardia was more pronounced compared to younger mice. Atrioventricular conduction was not affected. Older mice showed a higher S1PR3 expression in a naïve state and receptor expression was reduced after fingolimod administration. Combination with duloxetine or tolterodine alleviated fingolimod induced heart rate decrease. Our data provide preclinical evidence that negative chronotropic effects of fingolimod might be age dependent, possibly due to an altered expression and internalization of cardiac S1PR3 in older animals. This data could be relevant for future clinical monitoring and patient selection in the aging MS population. Combinational therapies of fingolimod and duloxetine or tolterodine are well tolerated and safe without an increased risk for pronounced bradycardia or arrhythmia.Keywords
Funding Information
- Novartis Pharma
This publication has 21 references indexed in Scilit:
- Treatment With Duloxetine in Adults and the Incidence of Cardiovascular EventsJournal of Clinical Psychopharmacology, 2012
- GRK2-Dependent S1PR1 Desensitization Is Required for Lymphocytes to Overcome Their Attraction to BloodScience, 2011
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple SclerosisNew England Journal of Medicine, 2010
- A UK consensus on the management of the bladder in multiple sclerosisPostgraduate Medical Journal, 2009
- Sphingosine 1-Phosphate Receptor SignalingAnnual Review of Biochemistry, 2009
- Up-regulating Sphingosine 1-Phosphate Receptor-2 Signaling Impairs Chemotactic, Wound-healing, and Morphogenetic Responses in Senescent Endothelial CellsJournal of Biological Chemistry, 2008
- Treating patients with overactive bladder syndrome with antimuscarinics: heart rate considerationsBJU International, 2007
- The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein-Gated Potassium Channel IKAChAmerican Journal of Transplantation, 2005
- Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart RateJournal of Biological Chemistry, 2004
- The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate ReceptorsJournal of Biological Chemistry, 2002